| # | Title | Journal | Year | Citations |
|---|
| 1 | Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial | Lancet Oncology, The | 2021 | 260 |
| 2 | A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1) | Annals of Oncology | 2016 | 234 |
| 3 | Pervasive chromosomal instability and karyotype order in tumour evolution | Nature | 2020 | 221 |
| 4 | Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets | Cell Metabolism | 2021 | 211 |
| 5 | Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment | Radiation Oncology | 2012 | 172 |
| 6 | Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study | | 2022 | 141 |
| 7 | Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer | JAMA Oncology | 2021 | 92 |
| 8 | Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial | Lancet Oncology, The | 2022 | 92 |
| 9 | Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival | Annals of Oncology | 2014 | 82 |
| 10 | Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial | Lancet Oncology, The | 2022 | 66 |
| 11 | Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? | European Urology | 2020 | 51 |
| 12 | PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer | European Journal of Cancer | 2017 | 48 |
| 13 | Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients | Surgical Oncology | 2019 | 46 |
| 14 | Abdominal desmoplastic small round cell tumor without extraperitoneal metastases: Is there a benefit for HIPEC after macroscopically complete cytoreductive surgery? | PLoS ONE | 2017 | 45 |
| 15 | Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study | ESMO Open | 2021 | 36 |
| 16 | Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study | European Urology | 2022 | 34 |
| 17 | Prognostic Factors for Ovarian Epithelial Cancer in the Elderly | International Journal of Gynecological Cancer | 2015 | 29 |
| 18 | Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 | European Journal of Cancer | 2023 | 26 |
| 19 | Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network | Cancer | 2020 | 25 |
| 20 | LBA36 Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNET | Annals of Oncology | 2020 | 25 |
| 21 | New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices? | Cancers | 2020 | 25 |
| 22 | Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study | European Journal of Cancer | 2017 | 24 |
| 23 | The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma | Annals of Oncology | 2018 | 24 |
| 24 | Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial | Genome Medicine | 2021 | 24 |
| 25 | Association between CD8 and PD‐L1 expression and outcomes after radical prostatectomy for localized prostate cancer | Prostate | 2021 | 22 |
| 26 | Adjuvant chemotherapy for small, lymph node–negative, triple‐negative breast cancer: A single‐center study and a meta‐analysis of the published literature | Cancer | 2020 | 20 |
| 27 | Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact | Breast Cancer Research and Treatment | 2019 | 16 |
| 28 | 652O Dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): Results of the GETUG/AFU VESPER V05 phase III trial | Annals of Oncology | 2021 | 14 |
| 29 | Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors | Oncologist | 2022 | 14 |
| 30 | The use of ‘added benefit’ to determine the price of new anti-cancer drugs in France, 2004–2017 | European Journal of Cancer | 2021 | 13 |
| 31 | 579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC) | Annals of Oncology | 2021 | 13 |
| 32 | Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients | Annals of Oncology | 2022 | 12 |
| 33 | Validation of Neutrophil Count as An Algorithm-Based Predictive Factor of Progression-Free Survival in Patients with Metastatic Soft Tissue Sarcomas Treated with Trabectedin | Cancers | 2019 | 7 |
| 34 | The Psychological Distress of Cancer Patients following the COVID-19 Pandemic First Lockdown: Results from a Large French Survey | Cancers | 2022 | 7 |
| 35 | Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours | European Journal of Cancer | 2022 | 7 |
| 36 | Patients’ satisfaction in early breast cancer treatment: Change in treatment over time and impact of HER2-targeted therapy | Critical Reviews in Oncology/Hematology | 2015 | 5 |
| 37 | Case Report: Grade 2 Metastatic Pancreatic Neuroendocrine Tumor With Progression of One Metastasis After Pregnancy to Grade 3 Large-Cell Neuroendocrine Carcinoma: One Case Cured by Resection With Genomic Characterization of the Two Components | Frontiers in Oncology | 2021 | 5 |
| 38 | Impact of sarcopenia status of muscle-invasive bladder cancer patients on kidney function after neoadjuvant chemotherapy | Minerva Urology and Nephrology | 2021 | 4 |
| 39 | Phase 2 study of retifanlimab (INCMGA00012) in patients (pts) with selected solid tumors (POD1UM-203). | Journal of Clinical Oncology | 2021 | 4 |
| 40 | 657MO Antibiotic (ATB) therapy and outcome from nivolumab (N) in metastatic renal cell carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN multicentric phase II study | Annals of Oncology | 2021 | 4 |
| 41 | 272 Dostarlimab in advanced/recurrent mismatch repair deficient/microsatellite instability high or proficient/stable endometrial cancer: the GARNET study | | 2021 | 4 |
| 42 | Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists? | Journal of Clinical Oncology | 2022 | 4 |
| 43 | Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database | Gynecologic Oncology | 2021 | 3 |
| 44 | 76P Analysis of antitumor activity of dostarlimab by tumor mutational burden (TMB) in patients (pts) with endometrial cancer (EC) in the GARNET trial | Annals of Oncology | 2021 | 3 |
| 45 | 385 Safety and antitumor activity of dostarlimab in patients (PTS) with advanced or recurrent DNA mismatch repair deficient (DMMR) or proficient (MMRP) endometrial cancer (EC): results from the garnet study | | 2020 | 3 |
| 46 | CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response | Cancers | 2022 | 3 |
| 47 | A non-inferiority randomized phase III trial of standard immunotherapy versusreduced dose intensity in responding patients with metastatic cancer: MOIO study. | Journal of Clinical Oncology | 2022 | 3 |
| 48 | 1361MO 8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase III trial | Annals of Oncology | 2022 | 3 |
| 49 | Reply to Nirmish Singla and Vitaly Margulis’s Letter to the Editor re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018. The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition | European Urology | 2020 | 2 |
| 50 | 697P Impact of β-blockers (BB) on outcomes of metastatic renal cell carcinoma (mRCC) patients treated with nivolumab (N) | Annals of Oncology | 2021 | 2 |
